MedTrace Logo

The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males

NCT01276119 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2012-03-22

No results posted yet for this study

Summary

To evaluate the safety, tolerability, blood levels and effects of CDP6038 administered by intravenous infusion (iv) and subcutaneous (sc) injection.

Conditions

  • Pharmacokinetics

Interventions

BIOLOGICAL

CDP6038

100 mg/mL solution for injection Single infusion over 60 minutes

BIOLOGICAL

CDP6038

100 mg/mL solution for injection Single infusion over 120 minutes

BIOLOGICAL

CDP6038

100 mg/mL solution for injection Single sc injection

OTHER

Placebo

0.9% sodium chloride for injection Single infusion over 60 minutes

OTHER

Placebo

0.9% sodium chloride for injection Single infusion over 120 minutes

OTHER

Placebo

0.9% sodium chloride for injection Single sc injection

Sponsors & Collaborators

  • UCB Pharma

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call Center · +1 877 822 9493 (UCB)

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01276119 on ClinicalTrials.gov